Millennium Management
VERV

Millennium Management’s Verve Therapeutics VERV Stock Holding History

Millennium Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-61,000
Closed -$295K – 6490
2024
Q3 		$295K Sell
61,000
-39,000
-39% -$227K ﹤0.01% 5199
2024
Q2 		$488K Buy
+100,000
New +$629K ﹤0.01% 4607
2022
Q4 		– Sell
-70,400
Closed -$2.42M – 7086
2022
Q3 		$2.42M Buy
+70,400
New +$2.25M ﹤0.01% 3576

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Millennium Management's VERV Position: Q3 2025 in Review

Millennium Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 138,224 shares — an estimated $1.55M sold.

Millennium Management first reported a position in VERV in Q2 2021 and held it in 10 quarters. The position peaked at $24.7M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Millennium Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Millennium Management sold 138,224 Verve Therapeutics shares in Q3 2025, an estimated $1.55M.
  • Millennium Management first reported a position in Verve Therapeutics in Q2 2021 and held it in 10 quarters.
  • Millennium Management's Verve Therapeutics position peaked at $24.7M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.